Amgen’s Sotorasib’ Therapy Designation For Advanced and Metastatic NSCLC With KRAS G12C Mutation
Recently, Amgen (NASDAQ: AMGN) announced that the FDA (Food and Drug Administration) has granted the company’s investigational KRASG12C inhibitor, Sotorasib, Breakthrough Therapy designation for the treatment of locally advanced or metastatic non-small cell lung cancer with the KRAS G12C mutation